Neutrophil to Lymphocyte ratio is significantly reduced after Sodium glucose cotransporter-2 inhibitor treatment in patients with type 2 diabetes mellitus

Basit Öğe Kaydı
dc.authorscopusid57208134255
dc.contributor.authorKurtkulagi, Ozge
dc.date.accessioned2024-09-25T19:45:07Z
dc.date.available2024-09-25T19:45:07Z
dc.date.issued2022
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractBackground. Sodium glucose cotransporter-2 inhibitors (SGLT2i) are novel therapeutic agents that be-came available in the treatment of type 2 diabetes mellitus (T2DM). This group of antidiabetic agents are associated with reduced glycated hemoglobin (HbA1c), fasting glucose, body weight and body mass index (BMI) in diabetic patients. All those beneficial effects may also be associated with a reduction in inflammatory burden. The purpose of the study is to compare neutrophil to lymphocyte ratio (NLR), a novel inflammatory marker derived from hemo-gram, before and 6 months after SGLT2i treatment in diabetic subjects. We also aimed to compare fasting glucose, HbA1c and other metabolic parameters as well as anthropometric measures (weight, BMI) before and 6 month after initiation of SGLT2i therapy. Materials and methods. The subjects with type T2DM that show up in internal medicine outpatient clinics of Abant Izzet Baysal University Hospital between January 2021 and December 2021 were enrolled to the study. Pretreatment and posttreatment NLR and other parameters were compared. We also obtained pretreatment and posttreatment laboratory data including urea, creatinine, fasting glucose, HbA1c, glomerular fil-tration rate, aspartate and alanine transaminases, plasma sodium and potassium. Results. Fasting glucose was reduced from 195 ± 72 mg/dl in pretreatment period to 146 ± 53 mg/dl in posttreatment period (p < 0.001). HbA1c was reduced from 9.1 ± 1.7 % in pretreatment period to 7.7 ± 1.7 % in posttreatment period (p < 0.001). The NLR before treatment was 2.6 ± 1.2 % before SGLT2i treatment and was reduced to 2.2 ± 0.6 % in 6th month of SGLT2i therapy. NLR was significantly decreased after treatment (p = 0.003). Conclusions. We suggest that NLR levels could be a marker of reduced inflammatory burden in T2DM subjects receiving SGLT2i treatment. © 2022. The Authors.en_US
dc.identifier.doi10.22141/2224-0721.18.2.2022.1151
dc.identifier.endpage89en_US
dc.identifier.issn2224-0721
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85159686986en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage86en_US
dc.identifier.urihttps://doi.org/10.22141/2224-0721.18.2.2022.1151
dc.identifier.urihttps://hdl.handle.net/20.500.12491/12864
dc.identifier.volume18en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherZaslavsky Publishing Houseen_US
dc.relation.ispartofMiznarodnij Endokrinologicnij Zurnalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzYK_20240925en_US
dc.subjectfasting glucoseen_US
dc.subjectHbA1cen_US
dc.subjectinflammationen_US
dc.subjectneutrophil to lymphocyte ratioen_US
dc.subjectsodium glucose cotranspor-ter-2 inhibitoren_US
dc.subjecttype 2 diabetes mellitusen_US
dc.titleNeutrophil to Lymphocyte ratio is significantly reduced after Sodium glucose cotransporter-2 inhibitor treatment in patients with type 2 diabetes mellitusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu